法尼甾体X受体
医学
肝硬化
肝肠循环
核受体
戒毒(替代医学)
肝病
药理学
生物信息学
胆汁酸
转录因子
癌症研究
内科学
生物
病理
替代医学
生物化学
基因
作者
Chuan Hun Ding,Z. Wang,Xinyue Dou,Qiao Yang,Yan Ning,Steven Kao,Xianan Sang,Min Hao,Kuilong Wang,Mengyun Peng,Shuosheng Zhang,Xin Han,Gang Cao
标识
DOI:10.14336/ad.2023.0830
摘要
The farnesoid X receptor (FXR), a ligand-activated transcription factor, plays a crucial role in regulating bile acid metabolism within the enterohepatic circulation. Beyond its involvement in metabolic disorders and immune imbalances affecting various tissues, FXR is implicated in microbiota modulation, gut- to-brain communication, and liver disease. The liver, as a pivotal metabolic and detoxification organ, is susceptible to damage from factors such as alcohol, viruses, drugs, and high-fat diets. Chronic or recurrent liver injury can culminate in liver fibrosis, which, if left untreated, may progress to cirrhosis and even liver cancer, posing significant health risks. However, therapeutic options for liver fibrosis remain limited in terms of FDA- approved drugs. Recent insights into the structure of FXR, coupled with animal and clinical investigations, have shed light on its potential pharmacological role in hepatic fibrosis. Progress has been achieved in both fundamental research and clinical applications. This review critically examines recent advancements in FXR research, highlighting challenges and potential mechanisms underlying its role in liver fibrosis treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI